Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q4 2023 call → NO我们根据提供的电话会议记录,寻找一个具体的、可识别的产品/服务/计划,其中管理层明确表示客户反应超出预期,并且公司正在采取具体措施扩大投入。同时,该产品/服务目前仍占公司整体业务的小部分。 扫描记录: - 提到多个产品:PADCEV、XTANDI、Vepdegestrant、Braftovi、CDK4i、B6A、PCV疫苗、mRNA流感疫苗、GBT-601、Ponsegromab、Nurtec、Oxbryta、Abrysvo、Elrexfio、Velsipity、Litfulo等。 - 寻找“需求超出准备”的表述。例如,Abrysvo:市场“clearly ahead of everyone's expectations”,但公司说“We would like to do better than the 30-some percent share”,这暗示需求超出预期,但公司没有明确说“超出准备”或“正在扩大投入”。实际上,管理层说“we are very focused going forward on retail contracting”,但这是未来计划,不是当前行动。 - 其他产品如Nurtec:说“we were encouraged by Q4”,但未提及超出准备。 - 没有明确看到“客户反应超出公司准备”的明确表述。例如,没有说“需求超过我们预期,我们正在增加产能”之类的。 - 关于Seagen,说“we feel very good about the $10 billion”,但那是未来目标。 - 关于GBT-601,说“recent data presented at ASH 2023 demonstrated...”,但那是数据,不是当前需求。 - 关于PADCEV,说“recent FDA approval... doubles the addressable population”,但那是市场机会,不是当前需求超出准备。 仔细看,管理层提到“we are excited by the strength of the PADCEV EV-302 data and recent FDA approval”,但未说需求超出准备。 唯一可能的是Abrysvo,但管理层说“we would like to do better than the 30-some percent share”,这暗示他们想要更多份额,但未说需求超出准备。而且他们提到“we are very focused going forward on retail contracting”,但那是未来计划。 没有明确找到“客户反应超出准备”和“公司正在扩大投入”同时出现的例子。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).